A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A phase 1/2 trial of Peluntamig, Carboplatin, Etoposide in small-cell lung cancer and prostate cancer, run by Phanes Therapeutics, now recruiting.
Overview
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) is a phase 1/2 interventional study registered as NCT05652686 by Phanes Therapeutics, with 203 participants planned, started 2023-09-05 and due to reach its primary completion in 2027-12. Interventions recorded: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin. Conditions listed: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
- TrialA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Shares Etoposide, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.